Tempest Therapeutics appoints John Frederick to Board as Class III director
Tempest Therapeutics (TPST) appointed John Frederick, a 62-year-old retired executive with 30+ years of experience, as a Class III director effective October 13, 2026. Frederick previously served as CFO and Chief Transformation Officer at Skillsoft and held leadership roles at Indigo Ag and SumTotal.
How this was made
The 30-second read
Why it matters
The appointment is a standard governance disclosure with negligible price impact.
Market read
Low relevance for traders; no material change to business outlook.
What to watch
Potential future influence if the director brings strategic expertise, but no immediate effect.
Background
Tempest Therapeutics (TPST) filed an 8‑K with the SEC reporting a new board member.
Ticker impact
Tempest Therapeutics filed an 8‑K announcing the appointment of John Frederick as a Class III director effective Oct 13 2026.
minimal impact as the change is routine and does not affect operations.
Director appointments are standard corporate governance disclosures; no material change to strategy or finances is indicated.
Market effects
None; the biotech sector is unaffected by a single board change.
None; no regional market shift expected.
None; the filing is a routine corporate governance update.
Counterpoint
Unlikely to move the stock; any short‑term volatility would be speculative.
Key entities
- PersonJohn Frederick
Appointed Class III director, former CFO/CTO at Skillsoft.
- CompanyTempest Therapeutics, Inc.
Biotech firm filing the 8‑K.